Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
Can-Fite BioPharma reported positive results from its Phase 2a study of Namodenoson in advanced pancreatic cancer, achieving the primary safety endpoint and demonstrating durable overall survival in heavily pretreated patients. In the evaluable third-line population, median overall survival exceeded five months, with 62.5% of patients surviving at least five months and one second-line patient remaining alive for more than 18 months.
Key figures
- Drug Name
- Namodenoson
- Phase Of Trial
- Phase 2a
- Patients enrolled
- 20
- Longest survival months
- > 18
- Evaluable third line patients
- 8
- Median overall survival months
- > 5
- Survival rate 5 months percent
- 62.5
- Survival rate 7 months percent
- 37.5
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.